Trial Profile
Phase 1, Multicenter, Open-label, Dose-escalation Study of Sotatercept (ACE-011) in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Oct 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Sotatercept (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Biomarker
- 28 Oct 2021 Planned End Date changed from 1 Mar 2020 to 1 Jun 2022.
- 28 Oct 2021 Planned primary completion date changed from 1 May 2018 to 1 Jun 2022.
- 12 Aug 2019 Planned End Date changed from 1 Aug 2019 to 1 Mar 2020.